Bimodal Effect of Lithium Plasma Levels on Hippocampal Glutamate Concentrations in Bipolar II Depression: A Pilot Study

Carregando...
Imagem de Miniatura
Citações na Scopus
28
Tipo de produção
article
Data de publicação
2015
Título da Revista
ISSN da Revista
Título do Volume
Editora
OXFORD UNIV PRESS
Citação
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, v.18, n.6, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: The hippocampus has been highly implicated in the pathophysiology of bipolar disorder (BD). Nevertheless, no study has longitudinally evaluated hippocampal metabolite levels in bipolar depression under treatment with lithium. Methods: Nineteen medication-free BD patients (78.9% treatment-naive and 73.7% with BD type II) presenting an acute depressive episode and 17 healthy controls were studied. Patients were treated for 6 weeks with lithium in an open-label trial. N-acetyl aspartate (NAA), creatine, choline, myo-Inositol, and glutamate levels were assessed in the left hippocampus before (week 0) and after (week 6) lithium treatment using 3T proton magnetic resonance spectroscopy (1H-MRS). The metabolite concentrations were estimated using internal water as reference and voxel segmentation for partial volume correction. Results: At baseline, acutely depressed BD patients and healthy controls exhibited similar hippocampal metabolites concentrations, with no changes after 6 weeks of lithium monotherapy. A significant correlation between antidepressant efficacy and increases in NAA concentration over time was observed. Also, there was a significant positive correlation between the changes in glutamate concentrations over follow-up and plasma lithium levels at endpoint. Mixed effects model analysis revealed a bimodal effect of lithium plasma levels in hippocampal glutamate concentrations: levels of 0.2 to 0.49 mmol/L (n=9) were associated with a decrease in glutamate concentrations, whereas the subgroup of BD subjects with ""standard"" lithium levels (>= 0.50 mmol/L; n = 10) showed an overall increase in glutamate concentrations over time. Conclusions: These preliminary results suggest that lithium has a bimodal action in hippocampal glutamate concentration depending on the plasma levels.
Palavras-chave
bipolar disorder, depression, glutamate, hippocampus, lithium, magnetic resonance spectroscopy
Referências
  1. Amsterdam JD, 2008, J CLIN PSYCHOPHARM, V28, P171, DOI 10.1097/JCP.0b013e318166c4e6
  2. Beneyto M, 2007, NEUROPSYCHOPHARMACOL, V32, P1888, DOI 10.1038/sj.npp.1301312
  3. Bustillo Juan R, 2013, Dialogues Clin Neurosci, V15, P329
  4. Capizzano AA, 2007, J MAGN RESON IMAGING, V26, P1378, DOI 10.1002/jmri.21144
  5. Colla M, 2009, MOL PSYCHIATR, V14, P696, DOI 10.1038/mp.2008.26
  6. Dager Stephen R, 2008, Top Magn Reson Imaging, V19, P81, DOI 10.1097/RMR.0b013e318181e0be
  7. Du J, 2010, P NATL ACAD SCI USA, V107, P11573, DOI 10.1073/pnas.0913138107
  8. Ende G, 2000, ARCH GEN PSYCHIAT, V57, P937, DOI 10.1001/archpsyc.57.10.937
  9. First M., 1995, STRUCTURED CLIN INTE
  10. Frye MA, 2007, NEUROPSYCHOPHARMACOL, V32, P2490, DOI 10.1038/sj.npp.1301387
  11. Gasparovic C, 2006, MAGN RESON MED, V55, P1219, DOI 10.1002/mrm.20901
  12. Gigante AD, 2012, BIPOLAR DISORD, V14, P478, DOI 10.1111/j.1399-5618.2012.01033.x
  13. Gigante AD, 2014, WORLD J BIOL PSYCHIA, V15, P145, DOI 10.3109/15622975.2013.819120
  14. Guy W, 1976, ECDEU ASSESSMENT MAN, P218
  15. HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56
  16. HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800
  17. Howells FM, 2013, PROG NEURO-PSYCHOPH, V41, P1, DOI 10.1016/j.pnpbp.2012.10.026
  18. Khairova R, 2012, MOL MED REP, V5, P680, DOI 10.3892/mmr.2011.732
  19. Kleindienst N, 2005, EUR ARCH PSY CLIN N, V255, P72, DOI 10.1007/s00406-005-0574-x
  20. Konradi C, 2011, ARCH GEN PSYCHIAT, V68, P340, DOI 10.1001/archgenpsychiatry.2010.175
  21. Kraguljac NV, 2012, PSYCHIAT RES-NEUROIM, V203, P111, DOI 10.1016/j.pscychresns.2012.02.003
  22. Machado-Vieira R, 2014, EXP THER MED, V8, P1205, DOI 10.3892/etm.2014.1864
  23. Machado-Vieira R, 2009, BIPOLAR DISORD, V11, P92, DOI 10.1111/j.1399-5618.2009.00714.x
  24. Machado-Vieira R, 2014, WORLD J BIOL PSYCHIA, V15, P84, DOI 10.3109/15622975.2013.830775
  25. Machado-Vieira R, 2012, PHARMACOL BIOCHEM BE, V100, P678, DOI 10.1016/j.pbb.2011.09.010
  26. McCullumsmith RE, 2007, BRAIN RES, V1127, P108, DOI 10.1016/j.brainres.2006.09.011
  27. Phillips M, 2008, MOL PSYCHIATR, V13, P833, DOI 10.1038/mp.2008.65
  28. Phillips ML, 2014, AM J PSYCHIAT, V171, P829, DOI 10.1176/appi.ajp.2014.13081008
  29. Posse S, 2007, MAGN RESON MED, V58, P236, DOI 10.1002/mrm.21287
  30. PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604
  31. Quiroz JA, 2008, NEUROPSYCHOPHARMACOL, V33, P2551, DOI 10.1038/sj.npp.1301671
  32. Rybakowski JK, 1999, J PSYCHIAT RES, V33, P363, DOI 10.1016/S0022-3956(99)00014-X
  33. Senaratne R, 2009, PSYCHIAT RES-NEUROIM, V172, P205, DOI 10.1016/j.pscychresns.2008.07.007
  34. Soeiro-de-Souza MG, 2012, ACTA PSYCHIAT SCAND, V126, P332, DOI 10.1111/j.1600-0447.2012.01889.x
  35. Suppes T, 2008, J AFFECT DISORDERS, V111, P334, DOI 10.1016/j.jad.2008.02.004
  36. Teicher MH, 2012, P NATL ACAD SCI USA, V109, pE563, DOI 10.1073/pnas.1115396109
  37. Wansapura JP, 1999, JMRI-J MAGN RESON IM, V9, P531, DOI 10.1002/(SICI)1522-2586(199904)9:4<531::AID-JMRI4>3.0.CO;2-L
  38. Watson S, 2004, BRIT J PSYCHIAT, V184, P496, DOI 10.1192/bjp.184.6.496
  39. Young AH, 2010, J CLIN PSYCHIAT, V71, P150, DOI 10.4088/JCP.08m04995gre
  40. YOUNG RC, 1978, BRIT J PSYCHIAT, V133, P429, DOI 10.1192/bjp.133.5.429
  41. Yuksel C, 2010, BIOL PSYCHIAT, V68, P785, DOI 10.1016/j.biopsych.2010.06.016
  42. Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424